Pharmafile Logo

Qtern

- PMLiVE

Lilly commits additional $4.5bn for US manufacturing sites

The company has also opened its first dedicated genetic medicine facility in Indiana in the US

- PMLiVE

FDA gives Rare Paediatric Disease designation to Satellite Bio for urea cycle disorders

The mortality rates of UCDs exceeds 25%, with no curative treatment available for newborns

- PMLiVE

AstraZeneca reports positive phase 3 data for tozorakimab in COPD

COPD affects nearly 400 million people globally and is the third leading cause of death worldwide

- PMLiVE

Eli Lilly to acquire Kelonia Therapeutics in deal worth up to $7bn

The acquisition will help Lilly to expand its capabilities in cell and gene therapy

- PMLiVE

AC Immune amends agreement with Lilly to develop potential Alzheimer’s treatment

The agreement covers the development of new lead tau morphomer candidates

- PMLiVE

Lilly to acquire Centessa in deal worth up to $7.8bn

The companies aim to advance treatments for narcolepsy and other sleep-wake disorders

- PMLiVE

Lilly’s Foundayo approved by US FDA as oral GLP-1 for weight loss

Taken at any time of the day, the oral GLP-1 is the only pill to have no food or water restrictions

- PMLiVE

BMS’ Opdivo gets expanded FDA and EU approval for Hodgkin lymphoma

This type of cancer is the most common one diagnosed in teenagers

- PMLiVE

AstraZeneca’s Imfinzi approved in EU for early gastric and gastro-oesophageal cancers

This is the first and only perioperative immunotherapy approved to treat early gastric cancers

- PMLiVE

US FDA launches ultra-rare diseases framework

The draft guidance specifically discusses genome editing and RNA-based therapies

- PMLiVE

Novo Nordisk and Vivtex partner in deal worth up to $2.1bn

The companies aim to develop next-generation oral medicines for obesity and diabetes

- PMLiVE

PureTech’s deupirfenidone gets FDA and EC Orphan Drug Designations for idiopathic pulmonary fibrosis

Rare diseases are defined as conditions affecting fewer than 200,000 people in the US or fewer than five in 10,000 individuals in the European Union

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links